Ifosfamide in the treatment of relapsed lymphoma

被引：0

作者：

Reiser, M ^{[1
]}

Borchmann, P ^{[1
]}

Diehl, V ^{[1
]}

Engert, A ^{[1
]}

机构：

[1] Univ Cologne, Innere Med Klin 1, D-50924 Cologne, Germany

来源：

ONKOLOGIE | 1998年 / 21卷

关键词：

ifosfamide; non-Hodgkin's lymphoma; Hodgkin's lymphoma; salvage therapy; relapse;

D O I：

10.1159/000054967

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since 1977 ifosfamide has been used for the treatment of relapsed or refractory non-Hodgkin's and Hodgkin's lymphoma. Early phase I/II trials showed efficacy of the drug in patients previously treated with cyclophosphamide. Because of a suggested lack of cross-resistance towards cyclophosphamide, ifosfamide has been used in numerous regimens. Ifosfamide showed clearly efficacy in relapsed lymphoma with response rates between 50 and 70%, Nevertheless, the use of the drug did not show any improvement of long-term survival in this group of patients. Because of its proven efficacy in relapsed lymphoma, ifosfamide is likewise used in newer high-dose chemotherapy protocols followed by autologous stem cell transplantation and in continuous infusion schedules.

引用

页码：26 / 29

页数：4

共 50 条

[21] TREATMENT OF REFRACTORY AND RELAPSED NON-HODGKINS-LYMPHOMA (NHL) WITH IFOSFAMIDE (I), METHOTREXATE (M) AND ETOPOSIDE (VP16)
SANGSTER, G
LEYLAND, MJ
BRITISH JOURNAL OF CANCER, 1987, 55 (03) : 345 - 345
[22] High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin’s lymphoma
Igor Aurer
Damir Nemet
Zdravko Mitrović
Dino Dujmović
Sandra Bašić-Kinda
Ivo Radman
Dubravka Sertić
Fedor Šantek
Marko Kralik
Snježana Dotlić
Sanja Mazić
Boris Labar
Annals of Hematology, 2016, 95 : 1129 - 1136
[23] High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma
Aurer, Igor
Nemet, Damir
Mitrovic, Zdravko
Dujmovic, Dino
Basic-Kinda, Sandra
Radman, Ivo
Sertic, Dubravka
Santek, Fedor
Kralik, Marko
Dotlic, Snjezana
Mazic, Sanja
Labar, Boris
ANNALS OF HEMATOLOGY, 2016, 95 (07) : 1129 - 1136
[24] PILOT-STUDY AND RANDOMIZED TRIAL OF MITOXANTRONE AND IFOSFAMIDE FOR RELAPSED NON-HODGKINS-LYMPHOMA
PRESCOTT, RJ
LEONARD, RCF
ALLAN, NC
ANGUS, B
BARRETT, A
DAS, SN
DAWSON, AA
HEPPLESTON, A
LESSELLS, AM
LUCIE, NP
LUCRAFT, HH
MACKIE, MJ
MACLAREN, KS
MATHESON, LM
PARKER, AC
PROCTOR, SJ
SARKAR, TK
SOUKOP, M
STEWARD, WP
WHITE, JM
LEUKEMIA & LYMPHOMA, 1993, 11 (1-2) : 111 - 114
[25] ICE (Ifosfamide, carboplatin, and etoposide) Was the Best Salvage Regimen in Patients with Relapsed or Refractory Malignant Lymphoma
Kusano, Yoshiharu
Terui, Yasuhito
Nishimura, Noriko
Ueda, Kyoko
Tadahiro, Gunji
Nitta, Hideaki
Mishima, Yuko
Yokoyama, Masahiro
Tsuyama, Naoko
Takeuchi, Kengo
Hatake, Kiyohiko
BLOOD, 2014, 124 (21)
[26] Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients
Zinzani, PL
Tani, M
Molinari, AL
Stefoni, V
Zuffa, E
Alinari, L
Gabriele, A
Bonifazi, F
Albertini, P
Salvucci, M
Tura, S
Baccarani, M
HAEMATOLOGICA, 2002, 87 (08) : 816 - 821
[27] Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities
Tanaka, Norina
Imai, Yoichi
Yoshinaga, Kentaro
Shiseki, Masayuki
Tanaka, Junji
ANNALS OF HEMATOLOGY, 2020, 99 (11) : 2577 - 2586
[28] Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities
Norina Tanaka
Yoichi Imai
Kentaro Yoshinaga
Masayuki Shiseki
Junji Tanaka
Annals of Hematology, 2020, 99 : 2577 - 2586
[29] IFOSFAMIDE COMBINATIONS IN LYMPHOMA
CABANILLAS, F
SEMINARS IN ONCOLOGY, 1990, 17 (02) : 58 - 62
[30] IFOSFAMIDE COMBINATIONS IN SALVAGE TREATMENT OF NON-HODGKIN LYMPHOMA
NORBERG, B
SCANDINAVIAN JOURNAL OF HAEMATOLOGY, 1986, 37 (03): : 268 - 268

← 1 2 3 4 5 →